---
layout: landmark
layout: topic-review
title: "Hepatobiliary"
redirect_from:
  - /absite/09_07-hepatobiliary/
permalink: /landmark/topic-review/hepatobiliary/
---

# Hepatobiliary Review


<!-- Optional: tiny style tweak for compact, mobile-friendly tables -->
<style>
.qr-table { width:100%; }
.qr-table th, .qr-table td { padding:.4rem .5rem; border-top:1px solid #e5e7eb; vertical-align:top; }
.qr-note { margin:.25rem 0 .5rem; font-weight:600; }
</style>

---

<details markdown="1" open>
<summary><strong>Liver</strong></summary>

<br>

### Anatomy & Variants
- **Lobar/segmental anatomy:** Cantlie’s line (GB fossa → IVC) divides right/left lobes. Couinaud segments I–VIII; **I = caudate** (separate inflow; drains directly to IVC).
- **Portal triad (hepatoduodenal ligament):** common bile duct (lateral), portal vein (posterior), proper hepatic artery (medial).  
  *Pearl:* Pringle maneuver (porta clamp) **does not** stop hepatic vein bleeding.
- **Hepatic artery variants (common):** replaced **RHA** off SMA (behind pancreas, posterolateral to CBD); replaced **LHA** off left gastric (gastrohepatic ligament).
- **Venous drainage:** three hepatic veins → IVC; middle often joins left before IVC; accessory right hepatic veins common.
- **Foramen of Winslow:** anterior–portal triad; posterior–IVC; inferior–duodenum; superior–caudate.

### Physiology, Bilirubin & Bile
- **Synthesis/storage:** urea made in liver; stores fat-soluble vitamins + B12. Not synthesized in liver: vWF, factor VIII (endothelium).
- **Zone sensitivity:** Zone III (centrilobular) most ischemia-sensitive.
- **Resection tolerance:** up to ~75% of normal liver with adequate function (see FLR below).
- **Bilirubin pathway:** heme → biliverdin → **unconjugated bilirubin** → hepatic conjugation → biliary excretion → urobilinogen → urine **urobilin**.  
  - **Unconjugated ↑:** hemolysis, impaired uptake/conjugation (Gilbert, Crigler–Najjar).  
  - **Conjugated ↑:** secretion/excretion defects (hepatitis, obstruction).  
  - Hepatitis labs: very high AST/ALT, modest Alk Phos. Obstruction: very high Alk Phos, modest transaminases.
- **Bile composition:** bile salts, phospholipids (lecithin), cholesterol, bilirubin, proteins. GB concentrates bile; lecithin emulsifies fat.

### Viral Hepatitis
- **Acute:** avoid surgery; fulminant failure (B, D, E > A, C).  
- **Chronic risk:** B, C, D → chronic hepatitis ± HCC.  
- **Key:** HBV vaccine → anti-HBs only; recovery → anti-HBc + anti-HBs; HCV curable (DAAs). HEV pregnancy: fulminant risk. HBV+HDV: highest mortality.  
  *Pearl:* No biopsy needed for classic HCC imaging + elevated AFP.

### Liver Failure, Ascites & Encephalopathy
- **Cirrhosis:** most common failure; best synthetic marker **PT/INR**.  
- **Fulminant failure:** ~80% mortality; use King’s criteria for transplant.  
- **Encephalopathy:** triggers—GI bleed, infection (SBP), electrolytes, meds. **Tx:** lactulose (2–3 stools/day), protein restriction initially (≤70 g/d), consider BCAA; antibiotics only if infection.  
- **Ascites:** portal HTN lymph leak. **Tx:** Na/fluid restriction, **spironolactone**, paracentesis with albumin replacement (~1 g/100 mL removed), TIPS if refractory; SBP prophylaxis after SBP or variceal bleed.  
- **Hepatorenal syndrome:** stop diuretics, albumin + vasoconstrictors; definitive = transplant.  
- **SBP:** PMN >250; E. coli common. **Tx:** 3rd-gen cephalosporin; expect improvement ≤48 h.  
  *Pearl:* Post-partum liver failure + ascites → consider hepatic vein thrombosis.

### Portal Hypertension & Varices
- **Resistance sites:** presinusoidal (schisto, PVT), sinusoidal (cirrhosis), postsinusoidal (Budd–Chiari, constrictive pericarditis/CHF).  
- **Thresholds:** portal (wedged) >10 mmHg significant; rupture ≈ HVPG ≥12 mmHg.  
- **Collaterals:** gastroesophageal, rectal, umbilical.  
- **Bleed management:** resuscitate + antibiotics; airway if needed; **octreotide** → banding; **TIPS** if uncontrolled or early rebleed. **NSBB** for secondary prophylaxis; vasopressin+NTG if necessary.
- **Shunts:** **TIPS** (fast, encephalopathy risk); **distal splenorenal (Warren)** for Child A with bleeding only; **partial PV–IVC interposition** when TIPS unavailable and ascites predominant.
- **Umbilical hernia in ascites:** elective repair after ascites control; **mesh** if clean; no mesh for contaminated/urgent cases; aggressive postop ascites control.  
  *Pearl:* Ascites control best reduces recurrence/complications.

**Portal Hypertension – Treatment Map**  
{:.qr-note}

| Scenario / indication | First-line therapy | Procedure / shunt | Notes |
|---|---|---|---|
| **Acute variceal bleed** | Resuscitate + antibiotics → **octreotide** → **banding** | **TIPS** if uncontrolled/early rebleed | Intubate if airway risk; vasopressin+NTG as bridge |
| **Secondary prophylaxis** | **NS β-blocker** ± repeat banding | — | Reduces rebleed & mortality |
| **Refractory ascites** | Max diuretics, paracentesis + albumin | **TIPS** (if function adequate) | Watch encephalopathy |
| **Child A, isolated bleeding** | BB + banding | **Distal splenorenal (Warren)** | Doesn’t help ascites |
| **Ascites predominant; TIPS unavailable** | Medical optimization | **Partial PV–IVC interposition** | Calibrated side-to-side |
| **Extensive portal thrombosis; no shunt option** | Medical/endoscopic | **Devascularization** (rare) | Mostly historical |
{:.qr-table}

### Hepatic Vascular Disorders
- **Budd–Chiari:** RUQ pain, hepatosplenomegaly, ascites, failure; polycythemia vera risk. Dx venous-phase imaging/biopsy. **Tx:** shunt above obstruction; catheter tPA if acute.  
- **Splenic vein thrombosis:** isolated gastric varices; cause pancreatitis; **Tx: splenectomy** if bleeding.  
- **Portal vein thrombosis:** extrahepatic; hypercoagulable; ascites without failure; varices common (kids: MCC massive hematemesis). **Tx:** heparin if acute (avoid during active bleed); shunt if needed.

### Liver Abscesses
- **Pyogenic** (>80%): right lobe, biliary source common; **E. coli** #1. Dx aspiration. **Tx:** CT-guided drain + antibiotics (op if unstable/failure).  
- **Amebic:** solitary right-lobe; travel (Mexico) or ETOH; serology+. **Tx:** metronidazole (drain only if refractory/rupture).  
- **Echinococcus:** double-walled cyst; **don’t aspirate** (anaphylaxis). Preop albendazole → careful excision; scolicidal agent; avoid spillage.  
- **Schistosomiasis:** eosinophilia; water exposure; can cause variceal bleeding. **Tx:** praziquantel + variceal care.

### Tumors (Benign & Malignant)
- **Hemangioma:** most common benign; peripheral→central fill; bright T2; avoid biopsy. **Tx:** observe (resect if symptomatic). Rare Kasabach–Merritt.  
- **FNH:** women; central scar; Kupffer cells (sulfur colloid uptake). **Tx:** observe.  
- **Adenoma:** OCPs/anabolics; right lobe; ~10% malignant; bleed risk ↑ if >4–5 cm. **Tx:** stop OCPs (regress?) → resect if >4 cm/symptomatic/no regression; rupture → embolize then resect.  
  *Pearl:* Sulfur colloid uptake—**FNH +**, **adenoma –**.
- **HCC:** risks HBV/HCV, alcohol cirrhosis, hemochromatosis, A1AT, aflatoxin, PSC; lung = most common mets.  
  - **Dx:** arterial hyperenhancement with portal/delayed washout + ↑AFP → no biopsy.  
  - **Resection:** solitary, no major vascular invasion, adequate function. **FLR:** no cirrhosis ≥25%; Child A ~30–40%; use **PVE** if marginal. Margin goal ~1 cm.  
  - **Transplant:** early stage with moderate–severe cirrhosis; **Milan:** 1 < 5 cm **or** ≤3 all <3 cm; no macrovascular/extrahepatic spread.  
  - **Locoregional:** ablation (<5 cm), **TACE** (>5 cm or unresectable), EBRT if not ablation/TACE candidate.  
  - **Fibrolamellar:** young, noncirrhotic; **neurotensin** marker; better prognosis (recurs often).
- **Metastases:** far more common than primary (≈20:1). **CRC mets** resection if adequate FLR → ~35% 5-yr survival.

**HCC – Resection vs Transplant vs Bridge**  
{:.qr-note}

| Liver function / tumor status | Resection | Transplant | Bridge / Other |
|---|---|---|---|
| **No cirrhosis, solitary, no major vascular invasion** | **Yes** if FLR ≥25% | No | Ablation if ≤5 cm, but resection preferred |
| **Child A, early stage (no portal HTN)** | **Possible** (FLR ~30–40%) | Consider if not resectable | PVE if marginal FLR; ablation if ≤5 cm |
| **Child B–C, early stage meeting Milan** | Often **No** | **Yes** (Milan) | **TACE/ablation** as bridge to TXP |
| **Beyond Milan (multifocal)** | Rarely | No (unless downstaged) | Downstage with **TACE/ablation** ± trials |
| **Major vascular invasion / extrahepatic** | No (exceptions controversial) | No | Systemic/RT/clinical trial; palliation |
{:.qr-table}

<details markdown="1">
<summary><strong>Liver Q&amp;A Review (condensed)</strong></summary>

- What divides right/left lobes? **Cantlie’s line** (GB fossa → IVC).  
- Common hepatic artery variants? **Replaced RHA from SMA**; **replaced LHA from left gastric**.  
- Variceal rupture HVPG? **≈12 mmHg** (portal HTN >6–10 mmHg).  
- Best function marker in cirrhosis? **PT/INR**.  
- SBP diagnosis/tx? **PMN >250**, **3rd-gen cephalosporin**.  
- Budd–Chiari risk/tx? **Polycythemia vera**; **shunt above obstruction** ± catheter tPA (acute).  
- HCC FLR thresholds? **No cirrhosis ≥25%; Child A ~30–40%**.  
- Milan criteria? **1 <5 cm or ≤3 all <3 cm; no vascular/extrahepatic disease**.  
- FNH vs adenoma sulfur colloid? **FNH + / adenoma –**.  
- Umbilical hernia in ascites? Elective after control; **mesh** if clean; **no mesh** if contaminated/urgent.

</details>

</details>

---

<details markdown="1">
<summary><strong>Biliary</strong></summary>

<br>

### Anatomy & Physiology
- **GB position:** under segments IV–V. **Cystic artery** from right hepatic within Calot’s triangle (cystic duct lateral, CHD medial).  
- **Duct blood supply:** longitudinal at 3 & 9 o’clock (retroduodenal GDA medially; right hepatic laterally).  
- **Normal diameters:** CBD ≤6 mm (≤10 mm post-chole); GB wall ≤4 mm; pancreatic duct ≤4 mm.  
- **Sphincter of Oddi:** **morphine contracts**, **glucagon relaxes**.  
- **Ducts of Luschka** can leak postop; Rokitansky–Aschoff sinuses with chronic pressure.

### Gallstones & Cholecystitis (incl acalculous/emphysematous)
- **Stones:** ~10% prevalence; most asymptomatic → observe.  
  - **Cholesterol** (US majority): GB stasis/nucleation; mostly in GB.  
  - **Black pigment:** hemolysis/cirrhosis/TPN.  
  - **Brown pigment (primary CBD):** infection (β-glucuronidase); evaluate ampulla/diverticula; many need sphincteroplasty.  
- **Biliary colic:** transient cystic-duct obstruction; resolves 4–6 h → elective chole if stones on US.  
- **Acute calculous cholecystitis:** stones + wall >4 mm/pericholecystic fluid; HIDA most sensitive. **Tx:** early lap chole if fit; no “cool-off” benefit.  
  - **Too ill:** cholecystostomy → interval chole.  
  - **Pregnancy:** lap chole (prefer 2nd tri), open Hasson entry, low insufflation, left tilt.  
  - **Cirrhosis:** chole once compensated (experienced liver surgeon; correct coagulopathy).  
- **Acalculous cholecystitis:** burns/TPN/trauma/ICU; stasis/ischemia; **Tx:** chole or percutaneous drain if unstable.  
- **Emphysematous cholecystitis:** diabetics; *Clostridium perfringens*; urgent source control.

### Choledocholithiasis, Cholangitis & Obstruction (ERCP/MRCP/IOC)
- **Strong suspicion** (stone on imaging, cholangitis, bili >3, dilated CBD ≥6–7 mm): **pre-op ERCP** for clearance (IOC/lap CBD exploration if ERCP unavailable).  
- **Moderate suspicion** (abnl LFTs, mild bili ↑, gallstone pancreatitis without cholangitis): **MRCP** or **IOC** (ERCP if obstruction confirmed).  
- **Low suspicion:** proceed to chole without further testing.  
- **IOC stone:** flush + glucagon (×2 max); transcystic exploration if feasible; otherwise lap CBD exploration **or** post-op ERCP per resources.  
- **Cholangitis:** Charcot triad ± Reynolds pentad. **Tx:** fluids + antibiotics → **emergent ERCP** with sphincterotomy/extraction; **PTC** if ERCP fails; perform chole before discharge.  
  *Pearl:* Normal **GGT** has very high NPV for choledocholithiasis.
- **RYGB anatomy:** if GB present → chole + intra-op CBD exploration; if GB absent → double-balloon ERCP or lap transgastric ERCP.

**Choledocholithiasis – Workup Summary**  
{:.qr-note}

| Clinical likelihood | Typical findings | First test | Next step if positive | Definitive management |
|---|---|---|---|---|
| **Strong** | CBD stone on imaging, cholangitis, Tbili >3, CBD ≥6–7 mm | **ERCP** (diagnostic + therapeutic) | Sphincterotomy ± extraction/stent | Cholecystectomy same/next admission once sepsis controlled |
| **Moderate** | Abnl LFTs (not just bili), mild bili ↑, GSP without cholangitis | **MRCP** *or* **IOC** | If stone confirmed → ERCP or lap CBD exploration | Proceed to chole after duct clearance |
| **Low** | No labs/imaging suggesting CBD stone | **No pre-op imaging** | Intra-op IOC per surgeon preference | Standard chole; manage stones if found |
| **Post-chole retained stone** | Jaundice/colic after chole | **US ± MRCP** | **ERCP** (~95% clearance) | Stent if needed; treat stricture if present |
| **RYGB anatomy** | Altered access | — | Double-balloon ERCP **or** lap transgastric ERCP **or** intra-op exploration | Tailor to local expertise/resources |
{:.qr-table}

### Bile Duct Injury & Stricture
- **Etiology:** most after lap chole; excess cephalad fundus retraction/misidentification.  
- **Intra-op troubleshooting:** if hepatic ducts don’t fill on IOC → withdraw catheter, flush, Trendelenburg; **convert to open** if injury suspected.  
- **Partial (<50%) CBD injury:** possible primary repair; otherwise **hepaticojejunostomy (HJ)** (do not try to reach duodenum).  
- **Post-op bile leak:** drain collection; if bilious → **ERCP + sphincterotomy/stent** (cystic stump/small injuries/Luschka).  
- **Complete transection:** **PTC** to decompress → **HJ** (≤7 d: immediate if feasible; >7 d: delay 6–8 wk to allow tissue maturation).  
- **Benign late stricture:** ischemia after chole most common; **MRCP** roadmap; durable repair = **choledochojejunostomy** (after excluding malignancy).

### Benign GB (Polyps, Adenomyomatosis, Cholesterolosis)
- **Polyps management:**  
  - **≤5 mm:** observe.  
  - **6–9 mm:** annual US; **operate if high-risk** (stones, symptoms, sessile, rapid growth, infundibular polyp, wall abnormality, age >50).  
  - **≥10–18 mm:** **lap chole**.  
  - **>18 mm:** treat as **GB cancer**.  
- **Adenomyomatosis (RA sinuses):** not premalignant; chole if symptomatic.  
- **Cholesterolosis:** speckled mucosa; ceftriaxone can cause sludge/jaundice.  
- **Prophylactic chole**: consider in transplant or RYGB candidates with stones.

**Gallbladder Polyp – Management Algorithm**  
{:.qr-note}

| Polyp size | High-risk features present?* | Action | Rationale |
|---|---|---|---|
| **≤5 mm** | No | Observe; no routine follow-up | Very low malignancy risk |
| **6–9 mm** | No | Annual US surveillance | Low risk; monitor growth |
| **6–9 mm** | **Yes** | **Cholecystectomy** | Stones, sessile, rapid growth, infundibular polyp, wall changes, age >50 |
| **≥10–18 mm** | — | **Cholecystectomy** | Size threshold for malignancy risk |
| **>18 mm** | — | Treat as **GB cancer** | High malignant potential |
{:.qr-table}

\*High-risk features: gallstones, symptoms, sessile morphology, rapid growth, infundibular location, wall abnormality, age >50.

### Malignancy & Choledochal Cysts
- **Gallbladder adenocarcinoma:** RFs—stones (#1), polyps ≥10 mm, porcelain GB (risk lower than once thought), typhoid, PSC/IBD; liver most common metastasis.  
  - **Incidental T1a (lamina propria):** chole only.  
  - **≥T1b (muscularis):** chole + wedge of IVb/V + portal LND; extend for margins. **No port-site excision**.  
- **Cholangiocarcinoma:** intrahepatic or extrahepatic; RFs—PSC, choledochal cysts, stones, liver flukes, HBV/HCV.  
  - **Dx:** MRCP/contrast MRI ± laparoscopy; resect if no distant or prohibitive nodal disease (avoid SMA/celiac nodes in extrahepatic disease).  
  - **Hilar (Klatskin):** often unresectable; distal → Whipple. **Transplant not for multifocal cholangio.**  
- **Choledochal cysts (Todani):** majority extrahepatic; malignant potential ~15%.  
  - **I:** excision + HJ. **II:** diverticulum excision ± Roux. **III:** transduodenal excision or sphincteroplasty. **IVa:** hepatic resection + biliary reconstruction. **IVb:** excision + HJ. **V (Caroli):** transplant (partial resection if localized).

### Cholestatic Diseases (PSC / PBC)
- **PSC:** men; UC association; multifocal strictures; pruritus/jaundice; risks—cirrhosis, cholangiocarcinoma. **Tx:** cholestyramine/UDCA symptom control; dilations/stents PRN; **transplant** for failure.  
- **PBC:** women; antimitochondrial Ab+; cholestasis → portal HTN. **Tx:** UDCA ± cholestyramine; **transplant** for failure.

### Special Situations & Hemobilia
- **Gallstone ileus:** cholecystoenteric fistula → SBO (IC valve common). **Tx:** proximal enterotomy and stone extraction; **avoid** same-setting chole + fistula takedown.  
- **Post-lap chole shock:** early = hemorrhage (cystic-artery clip); **late = septic shock** from clipped CBD → cholangitis.  
- **Pneumobilia:** prior ERCP/sphincterotomy most common; also gallstone ileus/infection.  
- **Hemobilia:** hepatic artery–bile duct fistula (trauma, PTC). UGIB with blood from ampulla; **Tx: angioembolization**.

<details markdown="1">
<summary><strong>Biliary Q&amp;A Review (condensed)</strong></summary>

- CBD diameter norms? **≤6 mm** (≤10 mm post-chole).  
- Sphincter pharmacology? **Morphine contracts; glucagon relaxes.**  
- Cholecystitis in pregnancy? **2nd-trimester lap chole; Hasson; low insufflation; left tilt.**  
- Strong CBD stone suspicion? **Pre-op ERCP** (or IOC/lap exploration if unavailable).  
- Cholangitis decompression? **ERCP** (PTC if ERCP fails).  
- IOC doesn’t show ducts? **Withdraw/flush; Trendelenburg; convert to open if injury suspected.**  
- Post-chole bile leak? **Drain + ERCP/stent**.  
- Complete transection timing? **≤7 d immediate HJ if feasible; >7 d delay 6–8 wk.**  
- GB polyp thresholds? **6–9 mm US yearly; ≥10 mm chole; >18 mm treat as cancer** (+ operate for high-risk features).  
- Isolated gastric varices cause? **Splenic vein thrombosis → splenectomy.**

</details>

</details>

---

## Figures

![Figure from page 66](./images/09_07-hepatobiliary_p66_i1.png)
![Figure from page 67](./images/09_07-hepatobiliary_p67_i1.png)
![Figure from page 68](./images/09_07-hepatobiliary_p68_i1.png)
![Figure from page 70](./images/09_07-hepatobiliary_p70_i1.png)
![Figure from page 73](./images/09_07-hepatobiliary_p73_i1.png)
![Figure from page 75](./images/09_07-hepatobiliary_p75_i1.png)
![Figure from page 77](./images/09_07-hepatobiliary_p77_i1.png)
![Figure from page 79](./images/09_07-hepatobiliary_p79_i1.png)
![Figure from page 80](./images/09_07-hepatobiliary_p80_i1.png)
![Figure from page 82](./images/09_07-hepatobiliary_p82_i1.png)
